Biogen Idec, Inc. (Massachusetts): European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorization Application for FAMPYRA

Biogen Idec (NASDAQ: BIIB) announced today that FAMPYRA® (prolonged-release fampridine tablets) has been granted a positive opinion for conditional approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Based on the CHMP recommendation, Biogen Idec expects that a marketing authorisation for FAMPYRA should be granted within 67 days.